niacinamide has been researched along with Cholera Infantum in 17 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC)." | 3.80 | Management of sorafenib-related adverse events: a clinician's perspective. ( Brose, MS; Frenette, CT; Keefe, SM; Stein, SM, 2014) |
| "Sorafenib, a tyrosine kinase inhibitor, is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC)." | 3.80 | Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective. ( Grande, C; Walko, CM, 2014) |
| " This study investigated the safety, pharmacokinetics, and preliminary efficacy of sorafenib in combination with gemcitabine and cisplatin." | 2.77 | Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. ( Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M, 2012) |
| "Diarrhea was the most common GI event." | 2.50 | Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. ( Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M, 2014) |
| " With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair." | 2.45 | Adverse effects of anticancer agents that target the VEGF pathway. ( Chen, HX; Cleck, JN, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (35.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, G | 1 |
| Chen, S | 1 |
| Liang, L | 1 |
| Li, X | 1 |
| Tang, P | 1 |
| Rao, X | 1 |
| Pan, M | 1 |
| Xu, X | 1 |
| Li, Y | 1 |
| Yao, Y | 1 |
| Zhou, Y | 1 |
| Gao, J | 2 |
| Mo, S | 1 |
| Cai, S | 1 |
| Peng, J | 1 |
| Zhang, Z | 1 |
| Clevers, H | 1 |
| Hua, G | 1 |
| Lalani, AA | 1 |
| McKay, RR | 1 |
| Lin, X | 1 |
| Simantov, R | 1 |
| Kaymakcalan, MD | 1 |
| Choueiri, TK | 1 |
| Santoni, M | 1 |
| Conti, A | 1 |
| De Giorgi, U | 1 |
| Iacovelli, R | 1 |
| Pantano, F | 1 |
| Burattini, L | 1 |
| Muzzonigro, G | 1 |
| Berardi, R | 1 |
| Santini, D | 1 |
| Cascinu, S | 1 |
| Brose, MS | 1 |
| Frenette, CT | 1 |
| Keefe, SM | 1 |
| Stein, SM | 1 |
| Walko, CM | 1 |
| Grande, C | 1 |
| Chen, HX | 1 |
| Cleck, JN | 1 |
| Reig, M | 1 |
| Matilla, A | 1 |
| Bustamante, J | 1 |
| Castells, L | 1 |
| de La Mata, M | 1 |
| Delgado, M | 1 |
| Moreno, JM | 1 |
| Forner, A | 1 |
| Varela, M | 1 |
| Sorà , F | 1 |
| Chiusolo, P | 1 |
| Metafuni, E | 1 |
| Bellesi, S | 1 |
| Giammarco, S | 1 |
| Laurenti, L | 1 |
| Ausoni, G | 1 |
| Zini, G | 1 |
| Bayer, AJ | 1 |
| Mario, B | 1 |
| Leone, G | 1 |
| Sica, S | 1 |
| Spigel, DR | 1 |
| Burris, HA | 1 |
| Greco, FA | 1 |
| Shipley, DL | 1 |
| Friedman, EK | 1 |
| Waterhouse, DM | 1 |
| Whorf, RC | 1 |
| Mitchell, RB | 1 |
| Daniel, DB | 1 |
| Zangmeister, J | 1 |
| Bass, JD | 1 |
| Hainsworth, JD | 1 |
| Schultheis, B | 1 |
| Kummer, G | 1 |
| Zeth, M | 1 |
| Brendel, E | 1 |
| Xia, C | 1 |
| Kornacker, M | 1 |
| Strumberg, D | 1 |
| FEINBLATT, TM | 1 |
| FEINBLATT, HM | 1 |
| FERGUSON, EA | 1 |
| BARBIERI, LL | 1 |
| FELIX, H | 1 |
| Staehler, M | 1 |
| Haseke, N | 1 |
| Schöppler, G | 1 |
| Stadler, T | 1 |
| Heinemann, G | 1 |
| Stief, CG | 1 |
| Newbold, HL | 1 |
| Mosher, LR | 1 |
| Pietranera, P | 1 |
| Rollier, R | 1 |
| Rollier, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study.[NCT02704767] | Phase 2 | 60 participants (Anticipated) | Interventional | 2016-06-30 | Not yet recruiting | ||
| A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer[NCT00600015] | Phase 2 | 166 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Progression free survival is defined as the time from the first day of treatment until the day tumor progression was documented. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST). Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions (1). Percentage of participants who were progression free at 6 month from the start of treatment is reported here. (NCT00600015)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Combination Therapy | 29 |
| Placebo | 22 |
"Disease Control Rate (DCR) is defined as the percentage of patients who have a partial/complete/stable response to therapy. Responses were assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.0).~Complete Response: Disappearance of all target lesions, and disappearance of all non-target lesions.~Partial Response: At least a 30% decrease in the sum of the longest diameter of target lesions (taking as reference the baseline sum of longest diameters) Stable Response: Neither sufficient shrinkage to qualify for partial response, nor sufficient increase to qualify for progressive disease (taking as reference the smallest sum of diameters since the treatment started)." (NCT00600015)
Timeframe: 18 months
| Intervention | percentage of participants (Number) |
|---|---|
| Combination Therapy | 54 |
| Placebo | 38 |
Duration of response is defined as the time from when objective response is realized until time to first documented disease progression. Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Objective Response = CR + PR. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00600015)
Timeframe: 18 months
| Intervention | months (Mean) |
|---|---|
| Combination Therapy | 4.6430 |
| Placebo | 5.2234 |
"Overall response rate (ORR) is defined as the percentage of patients who have a partial or complete response to therapy. Responses were assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.0).~Complete Response: Disappearance of all target lesions, and disappearance of all non-target lesions.~Partial Response: At least a 30% decrease in the sum of the longest diameter of target lesions (taking as reference the baseline sum of longest diameters)" (NCT00600015)
Timeframe: 18 months
| Intervention | percentage of participants (Number) |
|---|---|
| Combination Therapy | 8.1 |
| Placebo | 10.9 |
OS is defined as the time from the first treatment until date of death due to any cause. In the absence of confirmation of death or lack of data beyond follow-up period, the survival time was censored to last date the participant was known to be alive. (NCT00600015)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Combination Therapy | 7.62 |
| Placebo | 7.23 |
"Progression-free survival is defined as the time from the first day of treatment until the day tumor progression was documented. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST).~Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions" (NCT00600015)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Combination Therapy | 3.38 |
| Placebo | 1.94 |
3 reviews available for niacinamide and Cholera Infantum
| Article | Year |
|---|---|
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; | 2014 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Ga | 2006 |
2 trials available for niacinamide and Cholera Infantum
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Ci | 2012 |
12 other studies available for niacinamide and Cholera Infantum
| Article | Year |
|---|---|
SIRT1 inhibitors mitigate radiation-induced GI syndrome by enhancing intestinal-stem-cell survival.
Topics: Acetylation; Animals; Cell Survival; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Huma | 2021 |
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase II | 2017 |
Management of sorafenib-related adverse events: a clinician's perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue | 2014 |
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue | 2014 |
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovas | 2010 |
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase | 2011 |
Treatment of arteriosclerosis and vague abdominal distress with niacinamide hydroiodide, without side-effects.
Topics: Arteriosclerosis; Gastrointestinal Diseases; Niacin; Niacinamide; Nicotinic Acids | 1955 |
[Effect of nicotinamide overload on riboflavinuria in subjects without liver lesions and in liver disease patients].
Topics: Body Fluids; Gastrointestinal Diseases; Humans; Liver Diseases; Niacin; Niacinamide; Nicotinic Acids | 1954 |
[Deficiency in vitamin PP and colopathies].
Topics: Colon; Colonic Diseases; Disease; Gastrointestinal Diseases; Niacin; Niacinamide; Pellagra | 1962 |
Niacin and the schizophrenic patient.
Topics: Diazepam; Edema; Gastrointestinal Diseases; Humans; Liver Function Tests; Mental Disorders; Niacinam | 1970 |
[Therapeutic value of an association of phospholipids and adrenal cortex in hepatology].
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Glands; Adult; Aged; Asthenia; Biliary Tract Diseases; | 1971 |
[Treatment of lepromatous leprosy by ethionamide].
Topics: Adolescent; Adult; Age Factors; Aged; Avitaminosis; Child; Ethionamide; Female; Gastrointestinal Dis | 1972 |